JP2007500720A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500720A5 JP2007500720A5 JP2006522096A JP2006522096A JP2007500720A5 JP 2007500720 A5 JP2007500720 A5 JP 2007500720A5 JP 2006522096 A JP2006522096 A JP 2006522096A JP 2006522096 A JP2006522096 A JP 2006522096A JP 2007500720 A5 JP2007500720 A5 JP 2007500720A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- independently selected
- group
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims 94
- 239000001257 hydrogen Substances 0.000 claims 94
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 64
- 125000003710 aryl alkyl group Chemical group 0.000 claims 36
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims 33
- 125000001072 heteroaryl group Chemical group 0.000 claims 32
- 125000000623 heterocyclic group Chemical group 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 30
- 150000002431 hydrogen Chemical class 0.000 claims 30
- -1 chloro, methyl Chemical group 0.000 claims 28
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 25
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 25
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 18
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 18
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims 18
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 16
- 125000001153 fluoro group Chemical group F* 0.000 claims 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 108010087894 Fatty acid desaturases Proteins 0.000 claims 10
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 125000003367 polycyclic group Chemical group 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 230000005856 abnormality Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 230000002159 abnormal effect Effects 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- IIFDQESZTDBKEM-UHFFFAOYSA-N 3-(4-fluorophenyl)propan-1-amine Chemical compound NCCCC1=CC=C(F)C=C1 IIFDQESZTDBKEM-UHFFFAOYSA-N 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 102000055981 human SCD1 Human genes 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 1
- CKLFJWXRWIQYOC-UHFFFAOYSA-N 2-(4-fluorophenyl)ethanamine Chemical compound NCCC1=CC=C(F)C=C1 CKLFJWXRWIQYOC-UHFFFAOYSA-N 0.000 claims 1
- IMLAIXAZMVDRGA-UHFFFAOYSA-N 2-phenoxyethanamine Chemical compound NCCOC1=CC=CC=C1 IMLAIXAZMVDRGA-UHFFFAOYSA-N 0.000 claims 1
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- FGOUAQGATIHMQX-UHFFFAOYSA-N n-(2-phenylethyl)-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2C=NC(=NC=2)C(=O)NCCC=2C=CC=CC=2)CC1 FGOUAQGATIHMQX-UHFFFAOYSA-N 0.000 claims 1
- DAXBFBDXGVPOQZ-UHFFFAOYSA-N n-(3-methylbutyl)-2-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NCCC(C)C)=CN=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 DAXBFBDXGVPOQZ-UHFFFAOYSA-N 0.000 claims 1
- BDBOKIVURAOEDF-UHFFFAOYSA-N n-(3-methylbutyl)-4-(trifluoromethyl)-2-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-5-carboxamide Chemical compound N1=C(C(F)(F)F)C(C(=O)NCCC(C)C)=CN=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 BDBOKIVURAOEDF-UHFFFAOYSA-N 0.000 claims 1
- UVTGETXCJPTQCB-UHFFFAOYSA-N n-(3-phenylpropyl)-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2C=NC(=NC=2)C(=O)NCCCC=2C=CC=CC=2)CC1 UVTGETXCJPTQCB-UHFFFAOYSA-N 0.000 claims 1
- PNQGAOSCJVLAFG-UHFFFAOYSA-N n-benzyl-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2C=NC(=NC=2)C(=O)NCC=2C=CC=CC=2)CC1 PNQGAOSCJVLAFG-UHFFFAOYSA-N 0.000 claims 1
- OWUBZQNYYJEHEA-UHFFFAOYSA-N n-hexyl-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-2-carboxamide Chemical compound C1=NC(C(=O)NCCCCCC)=NC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 OWUBZQNYYJEHEA-UHFFFAOYSA-N 0.000 claims 1
- GADNSTZHYHGPJE-UHFFFAOYSA-N n-pentyl-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NCCCCC)=CN=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 GADNSTZHYHGPJE-UHFFFAOYSA-N 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 0 CC1=*I=C(N(C*2)C(*)(*)C(*)(*)N(**)C2(*)C2*=C2)N=I1 Chemical compound CC1=*I=C(N(C*2)C(*)(*)C(*)(*)N(**)C2(*)C2*=C2)N=I1 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- HWCKAMAVEWVBDO-UHFFFAOYSA-N 5-chloropyrazin-2-amine Chemical compound NC1=CN=C(Cl)C=N1 HWCKAMAVEWVBDO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49109503P | 2003-07-30 | 2003-07-30 | |
| US60/491,095 | 2003-07-30 | ||
| PCT/US2004/024658 WO2005011657A2 (en) | 2003-07-30 | 2004-07-29 | Piperazine derivatives and their use as therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007500720A JP2007500720A (ja) | 2007-01-18 |
| JP2007500720A5 true JP2007500720A5 (enExample) | 2007-09-13 |
| JP4838128B2 JP4838128B2 (ja) | 2011-12-14 |
Family
ID=34115467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522096A Expired - Fee Related JP4838128B2 (ja) | 2003-07-30 | 2004-07-29 | ピペラジン誘導体および治療剤としてのその用途 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7456180B2 (enExample) |
| EP (2) | EP1651620B1 (enExample) |
| JP (1) | JP4838128B2 (enExample) |
| KR (1) | KR20060037409A (enExample) |
| CN (3) | CN100558713C (enExample) |
| AT (1) | ATE532772T1 (enExample) |
| AU (2) | AU2004261268B2 (enExample) |
| BR (1) | BRPI0412348A (enExample) |
| CA (1) | CA2533901A1 (enExample) |
| EC (1) | ECSP066311A (enExample) |
| ES (1) | ES2377406T3 (enExample) |
| IL (1) | IL173396A0 (enExample) |
| MA (1) | MA28010A1 (enExample) |
| NO (1) | NO20060971L (enExample) |
| PL (1) | PL1651620T3 (enExample) |
| PT (1) | PT1651620E (enExample) |
| RU (1) | RU2006105717A (enExample) |
| SG (1) | SG145701A1 (enExample) |
| SI (1) | SI1648874T1 (enExample) |
| TN (1) | TNSN06033A1 (enExample) |
| WO (1) | WO2005011657A2 (enExample) |
| ZA (2) | ZA200600125B (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| PT1311269E (pt) | 2000-08-04 | 2012-05-10 | Dmi Biosciences Inc | Método de utilização de dicetopiperazinas e composição que contém as mesmas |
| KR20120101164A (ko) | 2003-05-15 | 2012-09-12 | 디엠아이 바이오사이언시스, 인크 | Ｔ-세포 매개성 질환의 치료 방법 |
| DE602004021206D1 (de) * | 2003-07-24 | 2009-07-02 | Euro Celtique Sa | Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen |
| US7754711B2 (en) | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| AU2004261267B9 (en) * | 2003-07-30 | 2009-04-09 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
| CA2533899C (en) | 2003-07-30 | 2011-01-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| BRPI0515499A (pt) * | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados de piridina para a inibição de estearoil-coa-desaturase humana |
| US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| AU2005286846A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| AR051026A1 (es) | 2004-09-20 | 2006-12-13 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| AU2005286647A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| WO2006101521A2 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| BRPI0515477A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd) |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| BRPI0516435B1 (pt) | 2004-10-29 | 2021-09-21 | Kalypsys , Inc | Composto, e composição farmacêutica |
| US7750011B2 (en) | 2005-02-15 | 2010-07-06 | Neurosearch A/S | Diazabicyclic aryl derivatives and their medical use |
| MY158766A (en) | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| WO2006125181A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their use as stearoyl-coa desaturase modulators |
| WO2006125178A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic pyridazine compounds and their uses as therapeutic agents |
| WO2006125180A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2006125179A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
| WO2007044085A2 (en) * | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| WO2006125194A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| JP2009513563A (ja) | 2005-06-03 | 2009-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体 |
| AU2006305769B2 (en) | 2005-10-25 | 2012-06-14 | Kalypsys, Inc. | Salts of modulators of PPAR and methods of treating metabolic disorders |
| JP2009515839A (ja) * | 2005-11-15 | 2009-04-16 | メルク フロスト カナダ リミテツド | ステアロイル−ＣｏＡデルタ−９デサチュラーゼ阻害剤としてのアザシクロヘキサン誘導体 |
| AU2006326815A1 (en) * | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| WO2007092435A2 (en) | 2006-02-07 | 2007-08-16 | Wyeth | 11-beta hsd1 inhibitors |
| PL2029572T3 (pl) | 2006-06-05 | 2011-05-31 | Novartis Ag | Związki organiczne |
| WO2008003753A1 (en) * | 2006-07-07 | 2008-01-10 | Biovitrum Ab (Publ) | Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity |
| JP2010501567A (ja) | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物 |
| WO2008043087A2 (en) * | 2006-10-05 | 2008-04-10 | Cv Therapeutics, Inc. | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| CA2665698A1 (en) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| AR064965A1 (es) * | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
| JP2008239616A (ja) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Ｈｄｌ上昇剤 |
| CA2682016A1 (en) * | 2007-03-28 | 2008-10-02 | Inovacia Ab | Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase |
| WO2008120759A1 (ja) * | 2007-03-30 | 2008-10-09 | Japan Tobacco Inc. | ウレア化合物およびその用途 |
| CA2685266C (en) | 2007-04-27 | 2014-01-28 | Purdue Pharma L.P. | Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal |
| US9321806B2 (en) | 2007-05-16 | 2016-04-26 | University Of Maryland, College Park | Methods for recovery of leaf proteins |
| US7842696B2 (en) * | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| GB0715055D0 (en) * | 2007-08-02 | 2007-09-12 | Smithkline Beecham Corp | Compounds |
| ATE488499T1 (de) | 2007-08-08 | 2010-12-15 | Graceway Pharmaceuticals Llc | Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen daraus |
| MX2010003117A (es) | 2007-09-20 | 2010-04-01 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de gpr119. |
| WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
| GB0722077D0 (en) | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| RU2010142936A (ru) * | 2008-03-20 | 2012-04-27 | Форест Лабораториес Холдингс Лимитед (Bm) | НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРАЗИНА КАК ИНГИБИТОРЫ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ |
| JP5856843B2 (ja) | 2008-05-27 | 2016-02-10 | アンピオ ファーマシューティカルズ，インコーポレイテッド | ジケトピペラジンを用いた医薬組成物 |
| SG10201703086VA (en) | 2008-10-17 | 2017-05-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their use as therapeutic agents |
| EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2010075356A1 (en) * | 2008-12-23 | 2010-07-01 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
| EP2398809B1 (en) | 2009-02-17 | 2015-07-08 | Merck Canada Inc. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| GB0907425D0 (en) * | 2009-04-29 | 2009-06-10 | Glaxo Group Ltd | Compounds |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| EP2459568A4 (en) | 2009-07-28 | 2013-02-27 | Merck Frosst Canada Ltd | NEW SPIRO COMPOUNDS AS AN INHIBITORS OF STEAROYL COENZYME A DELTA 9 DESATURASE |
| WO2011030139A1 (en) | 2009-09-11 | 2011-03-17 | Astrazeneca Ab | 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators |
| JP5752136B2 (ja) | 2009-10-14 | 2015-07-22 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | スピロ−オキシインドール化合物のための合成方法 |
| CN105726531A (zh) | 2010-02-26 | 2016-07-06 | 泽农医药公司 | 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途 |
| CA2810844C (en) | 2010-09-07 | 2017-03-21 | Dmi Acquisition Corp. | Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions |
| PE20141531A1 (es) | 2011-06-22 | 2014-10-23 | Purdue Pharma Lp | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos |
| EP2766029B1 (en) | 2011-10-10 | 2020-03-25 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
| MX2014003856A (es) | 2011-10-10 | 2015-01-16 | Ampio Pharmaceuticals Inc | Dispositivos medicos implantables con tolerancia inmune incrementada y metodos para hacerlos e implantarlos. |
| SG11201400283RA (en) | 2011-10-28 | 2014-03-28 | Ampio Pharmaceuticals Inc | Treatment of rhinitis |
| WO2013134546A1 (en) | 2012-03-07 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US9456998B2 (en) | 2012-05-22 | 2016-10-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Selective inhibitors of undifferentiated cells |
| AU2014232728B2 (en) | 2013-03-15 | 2019-02-21 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
| JP6484640B2 (ja) | 2014-02-14 | 2019-03-13 | 武田薬品工業株式会社 | Ｇｐｒ６のピラジンモジュレーター |
| EP4180041A1 (en) | 2014-08-07 | 2023-05-17 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| EP3183240A4 (en) | 2014-08-18 | 2018-06-27 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
| MA46589A (fr) | 2016-10-24 | 2019-08-28 | Yumanity Therapeutics Inc | Composés et utilisations de ces derniers |
| KR20190108118A (ko) | 2017-01-06 | 2019-09-23 | 유마니티 테라퓨틱스, 인크. | 신경계 장애의 치료를 위한 방법 |
| US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| MX2020009942A (es) | 2018-03-23 | 2021-01-08 | Yumanity Therapeutics Inc | Compuestos y usos de los mismos. |
| CN108570039B (zh) * | 2018-04-25 | 2022-09-23 | 上海美迪西生物医药股份有限公司 | 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用 |
| KR20220007845A (ko) | 2019-01-24 | 2022-01-19 | 유마니티 테라퓨틱스, 인크. | 화합물 및 이의 용도 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| EP4069367B1 (en) | 2019-12-06 | 2024-05-15 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| CN115772127B (zh) * | 2023-01-31 | 2023-05-16 | 山东佰隆医药有限公司 | 一种合成2-氰基-5-溴嘧啶的方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA983493A (en) * | 1972-10-11 | 1976-02-10 | Gilbert Regnier | Procede de preparation des derives du benzodioxole |
| DE2341925A1 (de) * | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| US4423049A (en) * | 1981-12-28 | 1983-12-27 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines |
| JPS6143173A (ja) * | 1984-08-06 | 1986-03-01 | Mitsui Petrochem Ind Ltd | 新規ピリミジン誘導体およびその製法 |
| JPS6187672A (ja) * | 1984-10-08 | 1986-05-06 | Mitsui Petrochem Ind Ltd | 新規ピリミジン誘導体 |
| US4734418A (en) * | 1984-12-14 | 1988-03-29 | Mitsui Petrochemical Industries, Ltd. | Quinazoline compounds and antihypertensives |
| JPS61238784A (ja) * | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| US4959368A (en) * | 1986-02-24 | 1990-09-25 | Mitsui Petrochemical Industries Ltd. | Therapeutic agent for neurological diseases |
| US5681956A (en) * | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| FR2701260B1 (fr) * | 1993-02-05 | 1995-05-05 | Esteve Labor Dr | Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments. |
| CN1088062C (zh) * | 1994-11-23 | 2002-07-24 | 纽罗根公司 | 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体 |
| US6288230B1 (en) * | 1998-09-29 | 2001-09-11 | Neurogen Corporation | 2-(2, 3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands |
| JP2003533978A (ja) | 2000-02-24 | 2003-11-18 | ゼノン ジェネティクス，インコーポレイテッド | トリグリセリド減少治療薬を同定するステアロイルＣｏＡデサチュラーゼを使用する方法と組成物 |
| GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| US7160878B2 (en) | 2000-07-27 | 2007-01-09 | Eli Lilly And Company | Substituted heterocyclic amides |
| CA2430987A1 (en) | 2000-09-26 | 2002-04-04 | Xenon Genetics, Inc. | Methods and compositions employing a novel stearoyl-coa desaturase-hscd5 |
| US20050014942A1 (en) * | 2001-10-30 | 2005-01-20 | Yasufumi Maruyama | Amide derivatives and drugs |
| EP1456175A1 (en) * | 2001-12-07 | 2004-09-15 | Eli Lilly And Company | Substituted heterocyclic carboxamides with antithrombotic activity |
| AU2003202115A1 (en) * | 2002-02-12 | 2003-09-04 | Pfizer Inc. | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh) |
| KR20040090978A (ko) * | 2002-03-13 | 2004-10-27 | 얀센 파마슈티카 엔.브이. | 히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체 |
| KR20040094672A (ko) | 2002-03-13 | 2004-11-10 | 얀센 파마슈티카 엔.브이. | 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체 |
| WO2003076400A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | New inhibitors of histone deacetylase |
| EP1501827A2 (en) * | 2002-04-25 | 2005-02-02 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| KR101146806B1 (ko) * | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
| CA2533899C (en) * | 2003-07-30 | 2011-01-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
-
2004
- 2004-07-29 EP EP04779656A patent/EP1651620B1/en not_active Expired - Lifetime
- 2004-07-29 RU RU2006105717/04A patent/RU2006105717A/ru not_active Application Discontinuation
- 2004-07-29 PL PL04779656T patent/PL1651620T3/pl unknown
- 2004-07-29 WO PCT/US2004/024658 patent/WO2005011657A2/en not_active Ceased
- 2004-07-29 PT PT04779656T patent/PT1651620E/pt unknown
- 2004-07-29 KR KR1020067002003A patent/KR20060037409A/ko not_active Ceased
- 2004-07-29 SG SG200805680-6A patent/SG145701A1/en unknown
- 2004-07-29 SI SI200431805T patent/SI1648874T1/sl unknown
- 2004-07-29 CN CNB200480021867XA patent/CN100558713C/zh not_active Expired - Fee Related
- 2004-07-29 AT AT04779656T patent/ATE532772T1/de active
- 2004-07-29 CA CA002533901A patent/CA2533901A1/en not_active Abandoned
- 2004-07-29 JP JP2006522096A patent/JP4838128B2/ja not_active Expired - Fee Related
- 2004-07-29 CN CN200910207686A patent/CN101693697A/zh active Pending
- 2004-07-29 BR BRPI0412348-4A patent/BRPI0412348A/pt not_active IP Right Cessation
- 2004-07-29 ES ES04779656T patent/ES2377406T3/es not_active Expired - Lifetime
- 2004-07-29 AU AU2004261268A patent/AU2004261268B2/en not_active Ceased
- 2004-07-29 EP EP10184745A patent/EP2316828A1/en not_active Withdrawn
- 2004-07-29 CN CNA2004800219422A patent/CN1829701A/zh active Pending
- 2004-07-29 US US10/567,009 patent/US7456180B2/en not_active Expired - Fee Related
-
2006
- 2006-01-05 ZA ZA200600125A patent/ZA200600125B/en unknown
- 2006-01-05 ZA ZA200600126A patent/ZA200600126B/en unknown
- 2006-01-25 EC EC2006006311A patent/ECSP066311A/es unknown
- 2006-01-26 IL IL173396A patent/IL173396A0/en unknown
- 2006-01-27 TN TNP2006000033A patent/TNSN06033A1/en unknown
- 2006-02-27 MA MA28838A patent/MA28010A1/fr unknown
- 2006-02-28 NO NO20060971A patent/NO20060971L/no not_active Application Discontinuation
-
2008
- 2008-10-08 US US12/247,792 patent/US8030488B2/en not_active Expired - Fee Related
-
2009
- 2009-06-11 AU AU2009202338A patent/AU2009202338A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500720A5 (enExample) | ||
| JP6353460B2 (ja) | Ｈｂｖ感染に対する抗ウイルス剤としての官能化ベンズアミド誘導体 | |
| CN103450077B (zh) | IRE-1α抑制剂 | |
| TWI236474B (en) | Antagonists of MCP-1 function and methods of use thereof | |
| TWI339121B (en) | 1-piperazine- and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic application thereof | |
| JP2008513498A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| JP2008513504A5 (enExample) | ||
| JP5342451B2 (ja) | Ｐｄｅ４阻害剤として有用な置換アセトフェノン | |
| JP2010528114A (ja) | 脂肪酸アミド加水分解酵素のヘテロアリール置換尿素モジュレータ | |
| AU2016323305A1 (en) | Hepatitis B core protein modulators | |
| JP2008513515A5 (enExample) | ||
| SG192439A1 (en) | Organic compounds | |
| AU2014310404B2 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| AU2018216954A1 (en) | Piperazine derivatives for influenza virus inhibition | |
| JP2005514455A (ja) | 芳香族チオエーテル肝臓ｘ受容体モジュレータ | |
| PT1142885E (pt) | Derivados de 2-(n-cianoimino)tiazolidin-4-ona | |
| EP3154634B1 (en) | Imidazol- or 1,2,4-triazol-derivatives and their use | |
| CN110885318A (zh) | 苯并恶唑衍生物及其制备方法和应用 | |
| WO2019105234A1 (zh) | 芳香族化合物及其药物组合物和用途 | |
| CN102516113B (zh) | 系列联苯醚衍生物以及在制备抗结核病药物方面的用途 | |
| WO2004069788A1 (ja) | カルボン酸化合物 | |
| BR112014028632B1 (pt) | composto, composição farmacêutica, e, método para preparar um composto | |
| JP7620629B2 (ja) | ＰＤＩＡ４阻害剤及びβ細胞発症機序を阻害し、糖尿病を治療するためのこのＰＤＩＡ４阻害剤の使用 | |
| WO2014092514A1 (ko) | 신규한 화합물, 이의 약학적으로 허용가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 |